Using GLP-1 in Perimenopause? This One Risk Your Doctor May Miss

Women 50 to 64 have the highest rate of GLP 1 use of any group, but these medications were not studied specifically in the context of perimenopause.

This video breaks down the muscle loss risk on semaglutide and tirzepatide, the research on combining GLP 1s with hormone therapy for better outcomes, and the specific protein, training, and cycling strategies that protect your body during treatment.

_______________________

CHAPTERS

00:00 Why Perimenopause Changes the GLP-1 Conversation
02:17 The Muscle Loss Risk Most Doctors Miss
04:20 The Research on GLP-1s and Hormone Therapy
06:30 Protein Needs on a GLP-1 in Perimenopause
07:19 Resistance Training and Digestive Support
08:59 What to Ask Your Doctor at Your Next Appointment

_______________________

Connect with me!
Facebook: https://www.facebook.com/drelizabethtaddiken/
Instagram: https://www.instagram.com/drelizabethtaddiken/
LinkedIn: https://www.linkedin.com/in/elizabeth-taddiken-nd-b1984732/

________________________

#PerimenopauseMoodChanges #HormonalHealth
#Misdiagnosis #WomensMentalHealth
#WomenOver40 #MidlifeWomen
________________________

MEDICAL DISCLAIMER: This video is for general information and educational purposes only and does not constitute the practice of medicine, the giving of medical advice, or the establishment of a doctor-patient relationship. The information provided is NOT intended to be a substitute for professional medical advice, diagnosis, or treatment, and is NOT intended to treat, diagnose, cure, or prevent any disease or medical condition. Always seek the guidance of your physician or qualified healthcare provider with any questions you may have regarding a medical condition. Do not delay or disregard seeking professional medical advice based on anything contained in this video. Do not make any changes to your health regimen, medications, or supplements without first consulting your physician or healthcare provider. Dr. Elizabeth Taddiken assumes no liability for any direct or indirect losses, damages, or adverse outcomes that may result from use of the information in this video. All content is provided for educational purposes only and is subject to change without notice.